Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 02, 2023

HER2/CEP17 FISH Ratio for Predicting Pathologic Complete Response Following Neoadjuvant Dual Anti-HER2 Therapy in Patients With HER2+ Breast Cancer

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
Oncologist 2022 Dec 10;[EPub Ahead of Print], EM Lander, KC Rappazzo, LC Huang, JR Hu, H Chen, Y Shyr, VG Abramson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading